For laboratory research use only — not for human or veterinary consumption.
The Peptide Index
Dosing guide

ACE-031 (Ramatercept) Dosage Chart & Schedule

ACE-031 (ramatercept) is a fusion protein linking the activin receptor type IIB extracellular domain to an antibody Fc region, designed to trap myostatin and related ligands and thereby increase muscle mass. It reached early human trials, including in boys with Duchenne muscular dystrophy, but development was halted over vascular safety signals. It is investigational and not approved.

Route
Subcutaneous
Frequency
Every 2-4 weeks (trials)
Half-life
Long, as expected for an Fc
Storage
Refrigerate 2-8 C; do not freeze (Fc-fusion biologic).
The short answer

ACE-031 (ramatercept) is an investigational myostatin-trap Fc-fusion protein whose clinical development was halted in 2013 over bleeding and vascular safety signals. Early trials, including in Duchenne muscular dystrophy, reported roughly 1-3 mg/kg subcutaneously every 2-4 weeks; it is not approved, and this is historical context only.

Figures describe how ACE-031 (Ramatercept) is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.

Dosage protocols

Commonly referenced research tiers. Start conservative; every compound and study context differs.

Most commonStandard
1-3 mg/kg
Weight-based; e.g. about 70-210 mg for a 70 kg adult
Frequency
Every 2-4 weeks (Phase 1/2 trials)
Weekly total
Not weekly; dosed every 2-4 weeks
Cycle
Development halted in 2013 over safety signals

Historical trial reference only; not approved and not recommended.

Development halted for safety

  • Trials were stopped in 2013 after bleeding and vascular safety signals (dilated vessels, gum and nose bleeding).
  • It reached Phase 1/2, including boys with Duchenne muscular dystrophy.
  • It is investigational, not approved, and there is no research-use dosing protocol.

Ready to run this protocol?

Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.

From vial to injection in 6 steps

1

Wipe both vial tops

Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.

2

Draw the water

Pull the planned amount of bacteriostatic water (2 mL) into the syringe.

3

Add it slowly

Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.

4

Let it dissolve

Wait until the solution is fully clear, then refrigerate the vial.

5

Draw your dose

Pull the calculated units on a U-100 insulin syringe.

6

Store between uses

Keep the reconstituted vial refrigerated and use within its stable window.

Handling & storage

  • As an Fc-fusion biologic it has a long half-life (about two weeks), so trials dosed every 2-4 weeks.
  • In trials it was handled as a sterile clinical solution, not a consumer-reconstituted powder.
  • If supplied as a research lyophilate, 1 mg + 2 mL bacteriostatic water is 500 mcg/mL (one unit about 5 mcg).
  • Research use only; the safety halt is the central dosing consideration.

ACE-031 (Ramatercept) dosing FAQ

What doses did ACE-031 trials use?

Phase 1/2 trials reported roughly 1-3 mg/kg subcutaneously every 2-4 weeks, reflecting its long Fc-fusion half-life. Development was halted, so this is historical context, not a recommendation.

Why is there no standard research dose?

Its clinical development was discontinued in 2013 over vascular and bleeding safety signals, so no ongoing or validated dosing protocol exists.

Why is it dosed so infrequently?

As an antibody Fc-fusion protein it has a half-life on the order of two weeks, which is why trials spaced doses every 2-4 weeks rather than daily.

Is ACE-031 the same as follistatin?

No. Both target the myostatin pathway to increase muscle, but ACE-031 is a soluble ActRIIB-Fc ligand trap, whereas follistatin binds and inhibits myostatin directly.

Sources

Full ACE-031 (Ramatercept) reference →All dosing charts →

Categories: Growth Hormone Secretagogues · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.